Tag Archives: Evidence-based practice

The FDA has spent nearly three decades telling drug developers what proof looks like. Earlier this year, it started revising that definition. A draft guidance updating how sponsors must demonstrate substantial evidence of effectiveness for human drug and biological products – the first such revision since 1998 – does more than reflect changes in drug development; it exposes a question ...

Read More »